Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease

NCT00055367 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00055367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, International, Multicenter, Open Label Study of the Safety, Tolerability and Effectiveness of Three Intravenous Infusions of Antegren (Natalizumab) in Adolescents With Moderately to Severely Active Crohn's Disease
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2002
Completion date
May 31, 2004
Enrollment
30
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease